Treatment of Guillain-Barré syndrome with anti-T cell monoclonal antibodies.
AUTOR(ES)
Feasby, T E
RESUMO
Three patients with acute Guillain-Barré syndrome were treated early in the course of the disease with OKT3, an anti-T-cell monoclonal antibody. Each patient developed acute lymphopenia with specific depletion of T3-positive lymphocytes. Two patients had continued progression of clinical deficits for eight and 14 days. This suggests that T lymphocytes may not be essential for progression of Guillain-Barré syndrome at this stage of the disease.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1014299Documentos Relacionados
- Anti-GM1 antibodies in patients with Guillain-Barré syndrome.
- Guillain-Barré syndrome following zimeldine treatment.
- Cytomegalovirus infections and anti-GM2 antibodies in Guillain-Barré syndrome.
- Encephalopathy associated with intravenous immunoglobulin treatment for Guillain-Barré syndrome.
- Hypokalaemia mimicking Guillain-Barré syndrome.
